THOMPSON JOHN CRAIG 4

What Happened

• John Craig Thompson, a director of Esperion Therapeutics, received an equity award on May 28, 2026. The Form 4 reports acquisition of 79,873 shares at $0.00 (transaction code A — award/grant). No cash payment was reported for the shares.

Key Details

• Transaction date and price: 2026-05-28; 79,873 shares at $0.00 (award/grant).
• Filing date: Form 4 filed 2026-06-01 (reporting period listed as 2026-05-28).
• Shares owned after transaction: not disclosed in the provided filing.
• Footnote (F1): The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the issuer’s next annual meeting of stockholders following May 28, 2026.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax-withholding, or late-filing flag was indicated in the provided data.

Context

• This was a compensation grant to a board member (not an open-market purchase or sale). Awards at $0.00 typically reflect equity compensation (e.g., restricted stock or RSUs) that are subject to vesting and may be nontransferable until vested.
• Such grants are routine for directors and do not, by themselves, indicate a personal buy/sell signal; they reflect company compensation practices.